Hamster models of COVID-19 pneumonia reviewed: How human can they be?

AD Gruber, TC Firsching, J Trimpert… - Veterinary …, 2022 - journals.sagepub.com
The dramatic global consequences of the coronavirus disease 2019 (COVID-19) pandemic
soon fueled quests for a suitable model that would facilitate the development and testing of …

[HTML][HTML] Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

ES Winkler, P Gilchuk, J Yu, AL Bailey, RE Chen… - Cell, 2021 - cell.com
SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered
neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism …

Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants

WR Strohl, Z Ku, Z An, SF Carroll, BA Keyt, LM Strohl - BioDrugs, 2022 - Springer
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …

Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy

I Ullah, J Prévost, MS Ladinsky, H Stone, M Lu… - Immunity, 2021 - cell.com
Neutralizing antibodies (NAbs) are effective in treating COVID-19, but the mechanism of
immune protection is not fully understood. Here, we applied live bioluminescence imaging …

SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for spillback to New World rodents

A Fagre, J Lewis, M Eckley, S Zhan, SM Rocha… - PLoS …, 2021 - journals.plos.org
Coronavirus disease-19 (COVID-19) emerged in late 2019 in China and rapidly became
pandemic. As with other coronaviruses, a preponderance of evidence suggests the virus …

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope

LA VanBlargan, LJ Adams, Z Liu, RE Chen, P Gilchuk… - Immunity, 2021 - cell.com
With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased transmissibility and potential resistance, antibodies and vaccines …

A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies

F Ferrara, MF Erasmus, S D'Angelo… - Nature …, 2022 - nature.com
As a result of the SARS-CoV-2 pandemic numerous scientific groups have generated
antibodies against a single target: the CoV-2 spike antigen. This has provided an …

Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomics

E Wyler, JM Adler, K Eschke, GT Alves, S Peidli, F Pott… - Molecular Therapy, 2022 - cell.com
For coronavirus disease 2019 (COVID-19), effective and well-understood treatment options
are still scarce. Since vaccine efficacy is challenged by novel variants, short-lasting …

In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike …

NC Das, P Chakraborty, J Bayry… - Frontiers in …, 2022 - frontiersin.org
Since the start of the pandemic, SARS-CoV-2 has already infected more than 250 million
people globally, with more than five million fatal cases and huge socio-economic losses. In …

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

P Maisonnasse, Y Aldon, A Marc, R Marlin… - Nature …, 2021 - nature.com
Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …